血清脂蛋白相关磷脂酶A2水平对颈动脉粥样硬化斑块及其稳定性预测价值的研究

doi:10.3969/j.issn.1673-5765.2019.09.006

摘要/Abstract

摘要：

目的研究血清脂蛋白相关磷脂酶A2（1ipoprotein-associated phospholipase A2，Lp-PLA2）水平对颈动脉粥样硬化斑块及其稳定性的预测价值。方法本研究患者来源于无症状性多血管床狭窄的社区研究 (A s y m p t o m at i c P o l y v a s c u l a r Abnormalities Community，APAC)。检测入组患者血清Lp-PLA2水平，通过超声评估颈动脉粥样硬化斑块特点。按照血清Lp-PLA2水平的四分位数，将受试者分为4组，用Logistic回归模型分析血清Lp-PLA2水平与颈动脉粥样硬化斑块及斑块稳定性的关系。结果高Lp-PLA2水平（＞159.1 ng/mL）是颈动脉不稳定斑块发生的预测因素（OR 2.8，95%CI 2.0～3.8，P <0.0001），在校正危险因素后，这种趋势没有发生变化（OR 1.7，95%CI 1.2～2.5，P＝ 0.0067），在＜60岁受试者中，该差异仍然存在（OR 1.7，95%CI 1.1～2.7，P =0.0142），但在≥60岁受试者中，其预测价值未达到统计学意义。结论较高血清Lp-PLA2水平是颈动脉不稳定粥样硬化斑块发生的预测因素，尤其在＜60岁患者中。

文章导读： 本研究是基于大样本社区人群数据库的研究，发现高水平血清Lp-PLA2是颈动脉粥样硬化不稳定斑块的危险因素。

Abstract:

Objective To investigate the association of serum total 1ipoprotein-associated phospholipase A2 (Lp-PLA2) level with the vulnerability of atherosclerotic carotid plaques. Methods Data of this cohort study were from Asymptomatic Polyvascular Abnormalities Community (APAC) study, which was a cross-sectional study. The data of serum Lp-PLA2 level and ultrasonographic assessment of carotid plaques were extracted and analyzed. The participants were divided into 4 groups based on the quartile of serum total Lp-PLA2 level. The multivariate logistic regression analysis was used to analyze the correlation between the serum total Lp-PLA2 level and carotid plaque development and vulnerability. Results A high Lp-PLA2 level (>159.1 ng/mL) was associated with carotid plaque vulnerability amongst the adults (OR 2.8, 95%CI 2.0-3.8, P <0.0001). After adjusting for the relevant risk factors, the tendency still existed (OR 1.7, 95%CI 1.2-2.5, P =0.0067). For subjects aged <60 years old, the correlation between the two variates still existed (OR 1.7, 95%CI 1.1-2.7, P =0.0142), while for subjects aged ≥60 years old, the difference of serum Lp-PLA2 level among the 4 groups had no statistical significance Conclusions An elevated serum Lp-PLA2 level was associated with carotid plaque vulnerability in adults, especially ones aged <60 years.

Key words: Lipoprotein-associated phospholipase A2; Carotid artery; Atherosclerosis plaque;Risk factor

申园, 王丹丹, 赵性泉. 血清脂蛋白相关磷脂酶A2水平对颈动脉粥样硬化斑块及其稳定性预测价值的研究[J]. 中国卒中杂志, 2019, 14(09): 882-888.

SHEN Yuan, WANG Dan-Dan, ZHAO Xing-Quan. Association between Serum Lipoprotein-associated Phospholipase A2 Level and Carotid Plaque Development and Vulnerability: a Cross-sectional Study[J]. Chinese Journal of Stroke, 2019, 14(09): 882-888.

参考文献

[1] CHENG S F，BROWN M M，SIMISTER R J，et

al. Contemporary prevalence of carotid stenosis in

patients presenting with ischaemic stroke[J]. Br J

Surg，2019，106（7）：872-878.

[2] REXRODE K. Sex differences in sex hormones，

carotid atherosclerosis，and stroke[J]. Circ Res，2018，

122（1）：17-19.

[3] FISHER M. Stroke. Geometry is destiny for carotid

atherosclerotic plaques[J]. Nat Rev Neurol，2012，8

（3）：127-129.

[4] LU M，PENG P，CUI Y，et al. Association of

progression of carotid artery wall volume and

recurrent transient ischemic attack or stroke：a

magnetic resonance imaging study[J]. Stroke，2018，

49（3）：614-620.

[5] SABA L，SAAM T，JAGER H R，et al. Imaging

biomarkers of vulnerable carotid plaques for

stroke risk prediction and their potential clinical

implications[J]. Lancet Neurol，2019，18（6）：559-

572.

[6] WU F，SONG H，MA Q，et al. Hyperintense plaque

on intracranial vessel wall magnetic resonance

imaging as a predictor of artery-to-artery embolic

infarction[J]. Stroke，2018，49（4）：905-911.

[7] SPENCE J D，SOLO K. Resistant atherosclerosis：

The need for monitoring of plaque burden[J]. Stroke，

2017，48（6）：1624-1629.

[8] RAI S，THALER D E，SALEHI P，et al. More to

atherosclerosis than stenosis：symptomatic carotid

artery with intraplaque hemorrhage[J/OL]. Stroke，

2017，48（4）：e104-e107. https：//doi.org/10.1161/

STROKEAHA.117.016923.

[9] BONNEFONT-ROUSSELOT D. Lp-PLA2，a

biomarker of vascular inflammation and vulnerability

of atherosclerosis plaques[J]. Ann Pharm Fr，2016，

74（3）：190-197.

[10] GUIBBAL F，MENEYROL V，AIT-ARSA I，et

al. Synthesis and automated labeling of [（18）F]

darapladib，a Lp-PLA2 ligand，as potential pet

imaging tool of atherosclerosis[J]. ACS Med Chem

Lett，2019，10（5）：743-748.

[11] OTSUKA F，ZHAO X，TROUT H H，et al.

Community-based statins and advanced carotid

plaque：role of CD163 positive macrophages in

lipoprotein-associated phospholipase A2 activity

in atherosclerotic plaque[J/OL]. Atherosclerosis，

2017，267：78-89. https：//doi.org/10.1016/

j.atherosclerosis.2017.10.014.

[12] ZALEWSKI A，MACPHEE C. Role of lipoprotein—

associated phospho-lipase A2 in atherosclerosis：

biology，epidemiology，and possible therapeutic

target[J]. Arterioscler Thromb Vasc Biol，2005，25

（5）：923-931.

[13] FENNING R S，BURGERT M E，HAMAMDZIC

D，et al. Atherosclerotic plaque inflammation varies

between vascular sites and correlates with response

to inhibition of lipoprotein-associated phospholipase

A2[J/OL]. J Am Heart Assoc，2015，4（2）：e001477.

https：//doi.org/10.1161/JAHA.114.001477.

[14] MARSCHE G. Lp-PLA2，plaque inflammation and

lesion development vary fundamentally between

different vascular sites[J/OL]. J Am Heart Assoc，

2015，4（2）：e001800. https：//doi.org/10.1161/

JAHA.115.001800.

[15] HUANG F，WANG K，SHEN J. Lipoproteinassociated

phospholipase A2：the story continues[J/

OL]. Med Res Rev，2019，https：//doi.org/doi：

10.1002/med.21597.

[16] FATEMI S，GOTTSATER A，ZARROUK M，et al.

Lp-PLA2 activity and mass and CRP are associated with incident symptomatic peripheral arterial

disease[J/OL]. Sci Rep，2019，9（1）：5609. https：//

doi.org/10.1038/s41598-019-42154-5.

[17] WANG Y，HU S，REN L，et al. Lp-PLA2 as a risk

factor of early neurological deterioration in acute

ischemic stroke with toast type of large arterial

atherosclerosis[J]. Sci Rep，2019，41（1）：1-8.

[18] ROSENSON R S，STAFFORINI D M. Modulation of

oxidative stress，inflammation，and atherosclerosis

by lipoprotein-associated phospholipase A2[J]. J

Lipid Res，2012，53（9）：1767-1782.

[19] LIU H，YAO Y，WANG Y，et al. Association

between high-sensitivity c-reactive protein，

lipoprotein-associated phospholipase A2 and carotid

atherosclerosis：a cross-sectional study[J]. J Cell

Mol Med，2018，22（10）：5145-5150.

[20] MOHLER E R 3rd，BALLANTYNE C M，

DAVIDSON M H，et al. The effect of darapladib

on plasma lipoprotein-associated phospholipase A2

activity and cardiovascular biomarkers in patients

with stable coronary heart disease or coronary heart

disease risk equivalent: the results of a multicenter,

randomized, double-blind, placebo-controlled

study[J]. J Am Coll Cardiol，2008，51（17）：1632-

1641.

[21] TIBUAKUU M，KIANOUSH S，DEFILIPPIS

A P，et al. Usefulness of lipoprotein-associated

phospholipase A2 activity and C-reactive protein

in identifying high-risk smokers for atherosclerotic

cardiovascular disease（from the Atherosclerosis

Risk in Communities study）[J]. Am J Cardiol，2018，

121（9）：1056-1064.

[22] SOFOGIANNI A，ALKAGIET S，TZIOMALOS

K. Lipoprotein-associated phospholipase A2 and

coronary heart disease [J]. Curr Pharm Des，2018，

24（3）：291-296.

[23] TSIMIKAS S，WILLEIT J，KNOFLACH M，et al.

Lipoprotein-associated phospholipase A2 activity，

ferritin levels，metabolic syndrome，and 10-year

cardiovascular and non-cardiovascular mortality：

results from the bruneck study[J]. Eur Heart J，2009，

30（1）：107-115.

[24] PERSSON M，BERGLUND G，NELSON J J，et

al. Lp-PLA2 activity and mass are associated with

increased incidence of ischemic stroke：a populationbased

cohort study from malmo，sweden[J].

Atherosclerosis，2008，200（1）：191-198.

[25] WASSERTHEIL-SMOLLER S，KOOPERBERG C，

MCGINN A P. Lipoprotein-associated phospiipasea，

hormone use，and the risk of ischemic stroke in

postmenopausal women[J]. Hypertension，2008，51

（4）：1115-1122.